StockData
Immunovant, Inc. logo

Immunovant, Inc. (IMVT) stock

IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$33.21−0.07 (-0.21%)

Close on Nov 17, 2026Market cap $6.86BP/E –Yield –

Immunovant enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Immunovant's enterprise value was $6.84B on Nov 11, 2026, against $3.69B a year earlier. Over the last 5 years it ranged from -$39.53M to $7.62B, with a median of $3.06B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$6.84B+74.8%
2025Dec 31, 2025$3.91B+24.0%
2024Dec 31, 2024$3.16B-40.1%
2023Dec 29, 2023$5.27B+216.5%
2022Dec 30, 2022$1.66B+295.4%
2021Dec 31, 2021$420.84M-89.7%
2020Dec 31, 2020$4.08B+2328.6%
2019Dec 31, 2019$167.88M–

More Immunovant figures

See a number that looks wrong?